# Real-World Tirzepatide Dosing: 74.2% Under 10 mg at the Sixth Fill | Buy This GLP

In a tirzepatide claims study, 74.2% of patients with a sixth fill received a dose below 10 mg. See how the study measured dosing and persistence.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/tirzepatide-most-never-reach-ten
Updated: 2026-11-14
Published: 2026-09-16

[← Research](https://buythisglp.com/research)

Evidence

# Real-World Tirzepatide Dosing: 74.2% Under 10 mg at the Sixth Fill

In a 20,998-person claims study, 74.2% of people with a sixth fill received a dose below 10 mg. The separate utilization analysis found 55.4% persistence at six months.

Editorial profile: [Neil Sanders](https://buythisglp.com/authors/neil-sanders)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20264 min readUpdated November 2026

At the sixth prescription fill · 74 in 100 fills were under 10 mg · Among patients with a sixth fill. · Optum claims cohort, 2022–2023.

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

A claims study of tirzepatide found that 74.2% of patients with a sixth fill received a dose below 10 mg [\[1\]](https://buythisglp.com/research/tirzepatide-most-never-reach-ten#ref-1). As you compare [prices that change by dose](https://buythisglp.com/tools/flat-or-rising), ask what each prescribed strength costs. A pharmacy claim records the dose dispensed and cannot verify how much a patient used.

## What the sixth fill showed

The study identified 20,998 adults without type 2 diabetes who started tirzepatide between May 2022 and September 2023. The utilization analysis used a smaller group (n = 3,459). At the sixth fill, the most common strength was 5 mg (33.0%), and 25.8% filled 10 mg or more.

The [six-month cost comparison](https://buythisglp.com/tools/six-month-cost) multiplies the published monthly rate by six. If the rate changes by dose, use the quoted price for each fill to estimate what you’ll pay.

## How many continued at six months

The study counted 55.4% of the utilization cohort as persistent at six months using a 60-day gap to define discontinuation. A further 30.8% switched to a different weight-loss medication or restarted tirzepatide after stopping. Our [review of longer-term treatment persistence](https://buythisglp.com/research/how-long-do-people-stay-on-a-glp1) covers other populations and follow-up periods. Those estimates answer a different question from this six-month claims analysis.

## Who was included in the weight-loss estimate

The effectiveness analysis included 239 people with no prior GLP-1 use who stayed on tirzepatide for at least six months and had weights recorded at baseline and six months. They lost an average of 11.9% of baseline weight. The study did not randomly assign doses, so that average cannot establish how much weight people lose at any particular strength.

If a seller asks you to pay up front, the [prepayment comparison](https://buythisglp.com/tools/term-and-prepay-check) helps separate the amount due from the advertised monthly average. Check the refund terms if your prescription, coverage, or ability to continue changes.

## Frequently asked

What dose did patients fill at their sixth prescription?

Among patients with a sixth fill, 74.2% filled a dose below 10 mg. That records what the pharmacy dispensed.

How many were still taking it?

Persistence was 55.4% at six months. A further 30.8% switched to another anti-obesity medication or GLP-1, or restarted tirzepatide after stopping.

Who was included in the six-month weight-loss estimate?

The average weight loss was 11.9% among 239 people with no prior GLP-1 use who stayed on tirzepatide for six months and had weight measurements at both time points. It was a group average across doses.

## Sources

1.  \[1\] Hankosky ER, et al. (2025). Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database Diabetes, Obesity and Metabolism. [PMID 39996368](https://pubmed.ncbi.nlm.nih.gov/39996368/)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
